A New Biological Front in MS: Fenebrutinib For Primary Progressive Multiple Sclerosis (PPMS)

For decades, Multiple Sclerosis (MS) research focused heavily on relapsing forms of the disease, leaving patients with progressive forms, where the central nervous system (CNS) experiences chronic, compartmentalized inflammation, with few options. While ocrelizumab revolutionized the field as the first approved therapy for PPMS, its administration via bi-annual infusions requires significant healthcare infrastructure.

Novel Mechanism of Action

Fenebrutinib introduces a novel mechanism of action: it is a potent, non-covalent, and highly selective BTK inhibitor. Unlike anti-CD20 therapies that primarily deplete B-cells in the periphery, fenebrutinib targets both B-cells and myeloid cells (such as microglia and macrophages) that are believed to drive the smoldering, invisible disability progression characteristic of progressive MS. Because it is a small molecule, fenebrutinib may also cross the blood-brain barrier more effectively, directly addressing the inflammation within the CNS.

First-Line Oral Therapy

The emergence of fenebrutinib as a potential first-line oral therapy for Primary Progressive Multiple Sclerosis (PPMS) marks a transformative moment in neurology, effectively challenging the long-standing dominance of infusion-based therapies. Recent findings from the pivotal Phase 3 FENtrepid study demonstrate that fenebrutinib, an investigational Bruton tyrosine kinase (BTK) inhibitor, met its primary endpoint by showing non-inferiority to ocrelizumab (Ocrevus) in slowing disability progression. This is a landmark achievement, as fenebrutinib is the first and only investigational agent to prove non-inferiority against an established anti-CD20 therapy in a Phase 3 PPMS trial.

Why It Matters

more on the novel mechanism of action

Fenebrutinib is an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor designed to penetrate the central nervous system (CNS) and treat inflammatory disease. Unlike most existing BTK inhibitors, which are covalent and irreversible and form a permanent bond with the enzyme, fenebrutinib is a reversible, non-covalent inhibitor that binds to BTK and later releases it. This mechanism, combined with its optimized pharmacokinetic profile and high potency, may help reduce off-target effects compared with traditional BTK inhibitors.

High Selectivity

Fenebrutinib is highly selective for BTK, approximately 130 times more selective than for other kinases, allowing it to target its intended pathway without significantly affecting other signaling systems. It can circulate systemically and cross the blood–brain barrier, enabling activity both in the body and within the CNS. The therapy is designed to address both relapsing and progressive disease biology by inhibiting B cells, which drive acute inflammatory relapses, and microglia in the brain, which are believed to contribute to chronic inflammation and long-term disability progression.

Clinical Parity and Structural Change

The FENtrepid study results (NCT04544449) are significant because they provide high-level evidence that a daily oral pill can offer the same level of neuroprotection as an intensive infusion regimen.

1. Redefining “Gold Standard” Efficacy

In the trial, fenebrutinib demonstrated a safety and efficacy profile comparable to ocrelizumab, specifically regarding the 12-week confirmed disability progression (CDP). This parity suggests that clinicians no longer have to trade efficacy for convenience. For patients, particularly those in the 50s and 60s who may be managing professional lives or limited mobility, the shift to an oral medication removes the patient-status burden of spending hours in a clinic twice a year.

2. Shifting the Infusion-Center Economics

Healthsystems currently rely on the revenue and operational models built around infusion chairs. However, the non-inferiority of an oral BTK inhibitor creates a fast track toward decentralized care.

• Capacity Management: Transitioning stable PPMS patients to fenebrutinib could free up thousands of infusion hours annually for other complex conditions.
• Geographic Equity: Patients in rural or underserved areas who lack proximity to high-volume referral centers can receive a gold standard therapy via a local pharmacy.

Who It Affects

patients

Primary Progressive Multiple Sclerosis (PPMS) is a distinct form of the disease affecting approximately 10% to 15% of the MS population. Unlike the more common relapsing forms, PPMS is characterized by a fairly steady, gradual decline in functional ability from the onset, without distinct periods of remission or recovery. This progressive course is primarily driven by nerve degeneration rather than episodic inflammation, and because spinal cord lesions are more prevalent than brain lesions in this type, walking difficulties are among the most common clinical challenges.

Diagnosis remains a complex process as no single symptom or laboratory test can confirm PPMS. Clinicians must integrate a variety of strategies, including detailed neurologic examinations, MRI monitoring to track lesion activity, and the exclusion of other potential causes of symptoms. Monitoring the disease course over time is essential, as the rate of progression varies significantly between individuals. These longitudinal evaluations help patients and providers make informed decisions regarding prognosis and the limited treatment options currently available.

Historically, treating PPMS has been difficult because most disease-modifying therapies (DMTs) target inflammation, which is less prominent in progressive stages. While research is rapidly evolving, highlighted by the development of BTK inhibitors, like fenebrutinib, and the use of the only currently FDA-approved DMT for progressive MS, the focus remains on identifying agents that can penetrate the central nervous system to address compartmentalized damage. Current management prioritizes early intervention and multidisciplinary care models to preserve independence and manage symptoms throughout the disease trajectory.

Expanding the Reach of Care

The data from the FENtrepid study, alongside the FENhance trials in relapsing MS, underscores that fenebrutinib’s impact spans the entire MS continuum.

• Patients with Smoldering MS: Many patients experience PIRA (Progression Independent of Relapse Activity). Fenebrutinib’s ability to inhibit both B-cell activation and microglial-mediated inflammation offers a dual-strike approach that infusion therapies may not fully address.
• Clinicians and Shared Decision-Making: Neurologists now face a more complex Assessment 5 (shared decision-making) session. They must balance the proven 10-year safety record of ocrelizumab against the novel, CNS-penetrant potential of fenebrutinib.
• Caregivers: By reducing the need for transportation to and from medical facilities for infusions, fenebrutinib reduces the logistical burden on family members who often coordinate these long appointments.

What Changes

The Move Toward CNS-Penetrant Therapy

The introduction of fenebrutinib necessitates a redesign of MS care pathways, shifting from peripheral depletion to intracranial inhibition.

1. Monitoring and Safety Governance

While fenebrutinib showed a favorable safety profile in Phase 3, with no new safety signals identified, the management of BTK inhibitors requires distinct protocols. Clinicians must monitor for potential liver enzyme elevations and ensure patients are up-to-date on vaccinations before starting therapy, as the drug modulates the immune system differently than CD20 depleters.

2. The TRAC Equivalent for MS: Tracking Progression

The Treatment-related amyloid clearance (TRAC) framework was developed by an Alzheimer’s Association workgroup to standardize the characterization of patients receiving anti-amyloid beta (Aβ) therapies. TRAC identifies pharmacodynamic changes in the brain based on biomarker evidence of amyloid deposit clearance. To meet the TRAC criteria, an individual must have pretreatment biomarker confirmation of amyloid deposits, receive an Aβ-targeting treatment, and show follow-up biomarker evidence of clearance. While future advancements may include blood tests, the workgroup currently recommends amyloid-positron emission tomography (PET) as the primary tool for defining TRAC.

The framework distinguishes between two primary categories of clearance:

• Full TRAC: Occurs when amyloid-PET levels drop below a predetermined positivity threshold, returning to a negative range.
• Partial TRAC: Describes a significant decrease in amyloid-PET levels that remains above the positivity threshold.

This classification is a dynamic biomarker status rather than a permanent trait; for example, data from trials show that amyloid can reaccumulate at a rate of approximately 3.4 Centiloids per year after treatment is stopped. TRAC is intended to guide clinical management, such as deciding when to stop dosing or transition to maintenance regimens, and to aid in the design of future clinical trials for Alzheimer’s disease.

Just as the TRAC framework is used in anti-amyloid therapies to track biological response, MS specialists are increasingly looking at neurofilament light (NfL) and paramagnetic rim lesions (PRLs) on MRI to monitor the efficacy of BTK inhibitors. Fenebrutinib’s potential to reduce these markers of chronic inflammation suggests it may address the unmet need of brain volume loss and disability accumulation more effectively over time.

Policy and Access: The New Frontier

The commercialization of fenebrutinib, led by Genentech and Roche, will likely trigger intense payer scrutiny.

• Pharmacy vs. Medical Benefit: Because fenebrutinib is an oral medication, it will typically fall under the pharmacy benefit, which can have different co-pay structures and prior-authorization hurdles compared to the medical benefit used for infusions.
• Sequencing and Step Therapy: Payers may attempt to mandate older or cheaper therapies before allowing access to a Phase 3-proven BTK inhibitor. However, the non-inferiority data against the current gold standard (ocrelizumab) provide a powerful clinical argument for early access.

Conclusion: A Scaling, Resilient Model of Care

The approval of fenebrutinib would mark a turning point in PPMS management, shifting the focus from symptomatic relief to intracranial biological modification. The Phase 3 FENtrepid data confirms that oral therapy is no longer a compromise. Instead, this data supports using oral therapy as a competitive, high-efficacy alternative.

By integrating this oral regimen into structured referral and monitoring pathways, healthsystems can move toward a more sustainable, scalable model of dementia and MS care. The future of progressive MS treatment lies in this multi-dimensional transformation: integrating diagnostic rigor, innovative pharmacology, and ethical frameworks that prioritize patient autonomy and equitable access.

References

1. https://www.roche.com/media/releases/med-cor-2026-02-07
2. https://clinicaltrials.gov/study/NCT04544449
3. https://www.nationalmssociety.org/understanding-ms/what-is-ms/types-of-ms/primary-progressive-ms
4. https://www.nationalmssociety.org/understanding-ms/what-is-ms/types-of-ms/primary-progressive-ms
5. https://clinicaltrials.gov/study/NCT04544449
6. https://www.gene.com/media/press-releases/15098/2026-02-07/genentechs-fenebrutinib-is-the-first-inv
7. https://pubmed.ncbi.nlm.nih.gov/41298245/